Global Uveitis Treatment Market Size

Uveitis Treatment Market Analysis

The Uveitis Treatment market will show rapid growth due to the increasing cases of uveitis and the development of novel drugs and treatments and it is expected to grow with a CAGR of 5.8% over the forecasted period.

The market for uveitis treatment is expected to be affected by the COVID - 19 outbreak which is majorly attributed to the lockdown being followed by major countries. Disrupted the supply chain had a direct impact on the market studied as many drugs could not reach the market on time. Uveitis patients are potentially at higher risk of exposure to infections including COVID-19. These above-mentioned elements are expected to burden the revenue trajectory of the global Uveitis Treatment market over the forecast period. However, as respective governing authorities have lifted these enforced lockdowns, the global Uveitis Treatment market is expected to recover accordingly.

The increasing prevalence of optical infections and chronic eye disorders across the globe represents is one of the key factors driving the growth of the market. Uveitis is highly prevalent among individuals suffering from diabetes, eye injuries, cataract, glaucoma, cystoid macular edema, band keratopathy, and autoimmune and inflammatory disorders. Furthermore, the market is being driven by the growing senior population, which is more sensitive to such disorders. If measures are not taken properly, these diseases can easily spread through human touch (through hands, clothes, or bedding) and by flies that have to meet discharges from an infected person's eyes or nose. In September 2021, a Non-profit group, Prevent Blindness, conducted awareness campaign on various forms of Inflammatory Eye Diseases (IED). In October 2021, ABIONYX Pharma announced the positive pre-clinical results for ER-001 in uveitis treatment and the development of first-class of biomedicines from its bio-HDL for the treatment of ocular pathologies. Thus, the government initiatives for the management of eye pathologies and rising R&D activities for the development of new therapies are some of the significant factors expected to drive the market growth.

Moreover, Trachoma is a disease of the eye caused by infection with the bacterium Chlamydia trachomatis. In March 2020, according to data published by World Health Organization (WHO), around 137 million people live in trachoma endemic areas and are at risk of trachoma blindness. Therefore, the high and increasing prevalence rate of these infectious diseases resulted in the increasing awareness regarding the available alternative treatments for managing uveitis are anticipated to drive the market further. Moreover, various technological advancements in the treatment alternatives, such as the development of non-steroidal injectables and anti-tumor necrosis factor (TNF) drugs, are acting as other growth-inducing factors.